Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Communications"
DOI: 10.1002/cac2.12150
Abstract: Dear Editor, Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation (ASCT) and salvage therapy with bendamustine, lenalidomide or bortezomib, mantle cell lymphoma (MCL) is… read more here.
Keywords: ibrutinib therapy; outcomes ibrutinib; mantle cell; retrospective analysis ... See more keywords